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Abstract
Aims/hypothesis Impaired nitric oxide (NO)-dependent
vasorelaxation plays a key role in the development of
diabetic vascular complications. We investigated the effect
of hyperglycaemia on impaired vasoreactivity and a
putative role therein of the AGE precursor methylglyoxal.
Methods The effects of high glucose and methylglyoxal on
NO-dependent vasorelaxation in isolated rat mesenteric
arteries from wild-type and transgenic glyoxalase (GLO)-I
(also known as GLO1) rats, i.e. the enzyme detoxifying
methylglyoxal, were recorded in a wire myograph. AGE
formation of the major methylglyoxal-adduct 5-hydro-5-
methylimidazolone (MG-H1) was detected with an anti-
body against MG-H1 and quantified with ultra-performance
liquid chromatography (tandem) mass spectrometry. Reac-
tive oxygen species formation was measured with a 5-(and-
6)-chloromethyl-2′7′-dichlorodihydrofluorescein diacetate
acetyl ester probe and by immunohistochemistry with an
antibody against nitrotyrosine.
Results High glucose and methylglyoxal exposure of
mesenteric arteries significantly reduced the efficacy of
NO-dependent vasorelaxation (p<0.05). This impairment
was not observed in mesenteric arteries of GLO-I transgenic
rats indicating a specific intracellular methylglyoxal effect.
The diabetes-induced impaired potency (pD2) in mesenteric
arteries of wild-type rats was significantly improved by
GLO-I overexpression (p<0.05). Methylglyoxal-modified
albumin did not affect NO-dependent vasorelaxation, while
under the same conditions the receptor for AGE ligand
S100b did (p<0.05). Methylglyoxal treatment of arteries
increased intracellular staining of MG-H1 in endothelial cells
and adventitia by fivefold accompanied by an eightfold
increase in the oxidative stress marker nitrotyrosine. Anti-
oxidant pre-incubation prevented methylglyoxal-induced
impairment of vasoreactivity.
Conclusions/interpretation These data show that hyper-
glycaemia-induced impairment of endothelium-dependent
vasorelaxation is mediated by increased intracellular methyl-
glyoxal levels in a pathway dependent on oxidative stress.
Keywords AGE.Endothelium.Glycation.Microvascular
disease.Oxidative stress.Rat
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CEL N
ε-(Carboxyethyl)lysine
CM-H2DCFDA 5-(and-6)-Chloromethyl-2′7′-
dichlorodihydrofluorescein diacetate
acetyl ester
CML N
ε-(Carboxymethyl)lysine
eNOS Endothelial nitric oxide synthase
GLO-I Glyoxalase-I
MG-H1 5-Hydro-5-methylimidazolone
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide
NA Numerical aperture
NAC N-Acetyl-L-cysteine
NO Nitric oxide
RAGE Receptor for AGE
ROS Reactive oxygen species
SNP Sodium nitroprusside
UPLC-MSMS Ultra-performance liquid chromatogra-
phy (tandem) mass spectrometry
Introduction
Diabetes mellitus is associated with an increased risk of
cardiovascular disease [1]. Endothelial dysfunction is consid-
ered to be the primary cause in the pathogenesis of vascular
disease in diabetes [1]. Although the mechanism whereby
diabetes leads to endothelial dysfunction is incompletely
understood, a common feature of endothelial dysfunction is
a decreased bioavailability of endothelium-derived nitric oxide
(NO) and, as a consequence, impaired endothelium-dependent
vasorelaxation [1]. Several studies havedemonstratedimpaired
endothelium-dependent vasorelaxation in diabetic patients [2,
3] and in animal models of diabetes [4, 5].
One hypothesis of how hyperglycaemia leads to endo-
thelial dysfunction and vascular complications is the
formation of AGEs [6]. AGEs are a heterogeneous family
of non-enzymatically modified proteins formed by carbo-
hydrates, which are increased in patients with diabetes
[7–9]. The mechanisms by which AGEs contribute to
vascular complications are multiple, including their inter-
action with the receptor for AGE (RAGE), the formation of
cross-links in basal membranes and intracellular accumula-
tion of glycated proteins [6]. Although it has been
demonstrated that AGEs are associated with impaired
endothelium-dependent vasorelaxation in type 2 diabetes
[10] and can reduce endothelium-dependent vasorelaxation
[11], it is not known which specific AGEs are the culprits
or which pathways are involved.
It is now apparent that especially intracellular sugars and
their derivatives can participate in glycation and AGE
formation [12]. The reactive dicarbonyl methylglyoxal has
received considerable attention as the most reactive AGE
precursor in endothelial cells [13]. Methylglyoxal is formed
non-enzymatically by dephosphorylation of triose phos-
phates and is efficiently catabolised to D-lactate by the
glyoxalase (GLO) pathway, consisting of GLO-I, GLO-II
and the co-factor glutathione [14]. Methylglyoxal primarily
reacts with arginine residues to form the major adduct
5-hydro-5-methylimidazolone (MG-H1) and with lysine to
form N
ε-(1-carboxyethyl)lysine (CEL) [15, 16]. Plasma
methylglyoxal levels are significantly increased in diabetic
patients [17] and in endothelial cells by hyperglycaemia
[18]. The importance of methylglyoxal and methylglyoxal-
derived AGEs for the development of diabetic vascular
complications and hypertension has only recently been
recognised. Recent studies have demonstrated that in-
creased methylglyoxal-derived AGE levels in diabetic
patients are associated with diabetic complications such as
nephropathy [19] and retinopathy [20], and with diabetes-
related vascular disorders such as hypertension [21–25]. As
a major precursor of AGE formation, methylglyoxal can
influence multiple aspects of cellular biology in diabetes
[26]. Methylglyoxal targets specific mitochondrial proteins
accompanied by an increase in the formation of reactive
oxygen species (ROS) [27]. Since ROS production by
mitochondria is responsible for major mechanisms involved
in diabetic complications, methylglyoxal-induced ROS
production may be an initial event in the pathogenesis of
vascular complications.
We hypothesised that accumulation of methylglyoxal can
lead to endothelial dysfunction by ROS formation and
therefore evaluated the effect of hyperglycaemia, methyl-
glyoxalandmethylglyoxal-modifiedalbuminonendothelium-
dependent NO-mediated vasorelaxation, a measure of
endothelial function, and tested the involvement of oxidative
stress therein.
Methods
Animals All animal studies were carried out in accordance
with the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health. All experiments
involving rats were reviewed and approved by the Ethics
Committee for animal care and use of Maastricht University,
the Netherlands.
GLO-I (also known as GLO1) transgenic rats were obtained
from T. Miyata [28]. Rat genomic DNA extracted from tail
tissue was used to detect the transgene by PCR using
specific primers for GLO-I or pBsCAG-2 vector. Primers
for cytomegalovirus enhancer, sense (5′-GTC GAC ATT
GAT TAT TGA CTA G-3′) and antisense (5′-CCA TAA
GGT CAT GTA CTG-3′), amplified a 350 bp fragment.
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3′ junction of vector, sense (5′-GTA GTG TGG GTG ACT
CCT CCG TTC CTT GGG-3′) and antisense (5′-TCG AGG
GAT CTT CAT AAG AGA AGA G-3′), amplified a
1,200 bp fragment. PCR amplification was carried out with
an initial denaturation at 95°C for 5 min, followed by 35
cycles of 95°C at 30 s, 55°C or 58°C at 30 s and 72°C at 30
or 75 s.
Wild-type rats (n=9) and transgenic GLO-I rats (n=8)
were made diabetic by intravenous injection of streptozotocin
(65 mg/kg body weight) in the tail vein. Weight- and age-
matched control rats (n=9) and transgenic GLO-I rats (n=8)
were not injected. Streptozotocin resulted in a fivefold
increase of blood glucose levels, irrespective of GLO-I
overexpression.
Methylglyoxal-modified albumin preparation and charac-
terisation Methylglyoxal was purchased from Sigma
Aldrich (St Louis, MO, USA) and methylglyoxal-
modified albumin was prepared by incubating human
albumin (Cealb; Sanquin, Amsterdam, the Netherlands) in
a phosphate buffer (0.2 mol/l), pH 7.8, with 0.5 or
10 mmol/l methylglyoxal for 2, 4 or 8 days. After
incubation, the preparations were extensively dialysed
against PBS at 4°C with three changes of solution. The
reagents were divided into aliquots and stored at 20°C.
N
ε-(carboxymethyl)lysine (CML), CEL and MG-H1 were
measured by ultra-performance liquid chromatography
(tandem) mass spectrometry UPLC-MSMS as previously
described [29].
Isometric tension measurements Healthy adult male wild-
type Wistar rats or adult Wistar rats with human GLO-I
overexpression (GLO-I TG) (300–450 g) were killed by
CO2 inhalation. Second-order mesenteric arteries were
isolated and then mounted in a myograph organ bath model
(610 M; Danish Myotechnology by J. P. Trading, Aarhus,
Denmark) with two steel 40 μm wires inserted through the
lumen of the segments. NO-mediated effects were selec-
tively investigated using acetylcholine (0.01–10.00 μmol/l)
and sodium nitroprusside (SNP; 0.01–10.00 μmol/l) during
contraction with 65 mmol/l K
+ (which blocks endothelium-
derived hyperpolarising factors), following preincubation
with the prostaglandin blocker indometacin (10 μmol/l)
(details, see Electronic supplementary material [ESM]).
Endothelial cell culture In the in vitro experiments we used
ECRF24 cells, which are derived from human umbilical
vein endothelial cells, immortalised using an amphotrophic,
replication-deficient retrovirus containing the E6/E7 genes
of human papilloma virus [30]. Most of the experiments
were also performed with HUVEC and showed similar
results to those with ECRF24. ECRF24 cells were cultured
on fibronectine-coated 75 cm
2 flasks and maintained at
37°C in 5% CO2. Culture medium consisted of M199 (with
Na2HCO3 and glutamine; Lonza, Basel, Switzerland)
containing 20% (vol./vol.) heat-inactivated fetal calf serum
(HyClone, Logan, UT, USA), 2 mmol/l glutamine
(Invitrogen, San Diego, CA, USA), 100 U/ml penicillin
Fig. 1 Effect of high glucose concentration on acetylcholine (ACh)-
induced NO-mediated endothelium-dependent relaxation in isolated
rat mesenteric arteries. a Rat mesenteric arteries were mounted in a
myograph and incubated with or without high glucose concentrations
for 2 h. Acetylcholine-induced NO-mediated endothelium-dependent
relaxation was impaired in a concentration-dependent manner during
incubation with 30 mmol/l glucose (white circles) or 40 mmol/l glucose
(black circles) compared with control (5 mmol/l glucose, white squares).
The 40 mmol/l glucose incubation resulted in a statistically significant
shift of the dose–response curve (*p<0.05 vs control group). Incubation
with 35 mmol/l mannitol (black squares) as an osmotic control did not
impair NO-mediated endothelium-dependent relaxation (n=6). b SNP-
induced NO-mediated endothelium-independent vasorelaxation during
incubation without (white squares) or with 40 mmol/l glucose (black
circles) for 2 h did not differ (n=6). c GLO-I activity in mesenteric
arteries homogenates of GLO-I transgenic (TG) rats was significantly
elevated compared with mesenteric arteries homogenates of wild-type
rats (***p<0.001, n=4). d In mesenteric arteries of GLO-I transgenic
rats, acetylcholine-induced NO-mediated endothelium-dependent relax-
ation was not impaired during incubation with 40 mmol/l glucose (black
circles) for 2 h compared with control incubations (5 mmol/l glucose,
white squares, n=5). e Acetylcholine-induced vasorelaxation was
significantly impaired in wild-type diabetic rats (black squares;
*p<0.05) compared with the controls (wild-type control, white squares;
transgenic control, white circles). GLO-I overexpression improved this
relaxation (black circles; n=8). f The decreased potency in wild-type
(WT) diabetic rats (**p<0.01) was significantly improved by GLO-I
overexpression (*p<0.05)
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endothelial cell growth factor (Sigma Aldrich) and 5 U/ml
heparin (Leo Pharma, Breda, the Netherlands).
Immunohistochemistry For immunohistochemistry, arteries
were fixed with phosphate-buffered (pH 7.4) formaldehyde
(4%, vol./vol.) for 30 min at 37°C at the end of the
myograph experiments. Subsequently, arteries were trans-
ferred to 70% (vol./vol.) ethanol embedded in paraffin and
processed for histological examination. An anti MG-H1
antibody was used to detect the major methylglyoxal-
adduct MG-H1 and a polyclonal nitrotyrosine antibody
(Calbiochem, San Diego, CA, USA) was used for detection
of peroxynitrite formation.
Immunofluorescence ECRF24 cells were seeded on chamber
slides (Lab-Tek II; Nunc, Rochester, NY, USA), fixed with
paraformaldehyde (4%, wt/vol.) and permeabilised with
Triton X-100 (0.1%, vol./vol.). Subsequently mouse anti-
MG-H1 IgG (1:5000) was used as the primary antibody and
FITC-conjugated anti-mouse IgG (1:30; Dako, Glostrup,
Denmark) was used as the secondary antibody. Localisation
was visualised with a confocal microscope (MRC600; Bio-
Rad Laboratories, Hemel Hempstead, UK) equipped with an
air-cooled argon–krypton mixed gas laser and mounted on to
an Axiophote microscope (Zeiss, Sliedrecht, the Netherlands)
using oil-immersion objectives (×40, numerical aperture
[NA] = 3D1.3; or ×63, NA=3D1.4). Cells incubated without
the primary antibodies were used to determine non-specific
background fluorescence.
GLO-I assay GLO-I activity was assayed by spectropho-
tometry accordingtothe methodofMcLellanandThornalley,
monitoring the increase in absorbance at 240 nm due to the
formation of S-D-lactoylglutathione for 10 min at 25°C [31].
Oxidative stress measurement Reactive oxygen species
were measured with the 5-(and-6-)-chloromethyl-2′7′-
dichlorodihydrofluorescein diacetate acetyl ester (CM-
H2DCFDA) assay (Invitrogen). In brief, endothelial cells
cultured in black 96 wells (Cellstar; Greiner, Monroe, NC,
USA) were loaded with 50 µmol/l CM-H2DCFDA for
45 min. Subsequently, cells were incubated with 1.0 mmol/l
methylglyoxal (with or without 100 µmol/l N-acetyl-L-
cysteine [NAC], 10 nmol/l EUK-134 and 10 nmol/l
Mn[III]TMP pre-treatment), with simultaneous fluorescent
signal (485/516 nm) measurement by micro-plate reader
(Synergy Biotek, Winooski, VT, USA) during 60 min.
Results are shown as arbitrary units (normalised fluorescent
signal produced during 60 min) ± SEM.
Cell viability assay To assess cell viability, a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT; Invitrogen) assay was used. Briefly, endothelial
cells were seeded at a density of 1×10
4 cells per well into
96-well culture plates. Confluent monolayers were then
exposed to various methylglyoxal concentrations (0.1, 0.33
and 1.0 mmol/l) for 60 min. Afterwards cells were
incubated with MTT for 3 h and lysed with hydrogen
chloride/isopropanol. Subsequently absorbance was mea-
sured at 570 nm and at 690 nm for background subtraction.
NO measurement Deoxygenated water was spiked with
•NO gas and the •NO concentration was monitored with an
Iso-NO meter (World Precision Instruments, Sarasota, FL,
USA) at 37°C and the decrease in •NO concentration
followed in time in the presence or absence of the test
compound in solution (for details, see ESM).
Statistical analysis All values are expressed as mean ±
SEM. Sensitivity (pD2) and maximum response (Emax)
were calculated from the concentration–response curves to
acetylcholine. pD2 was defined as the negative logarithm to
base 10 of the EC50 values and Emax was defined as the
maximal vasorelaxation to acetylcholine at the highest
concentration used and expressed as 100 minus percentage
relative contractions to 65 mmol/l K
+. The statistical
differences in potency and maximum response between
groups was tested using one-way ANOVA and the shift of
the dose–response curve was tested with two-way ANOVA
with a post hoc Bonferroni correction. A p value of less
than 0.05 was considered statistically significant.
Results
Hyperglycaemia-induced impairment of NO-mediated re-
laxation in rat mesenteric arteries is normalised by GLO-I
overexpression To investigate the effects of high glucose on
vascular reactivity, isolated mesenteric arteries were
mounted in a myograph and exposed to 30 and 40 mmol/l
glucose for 2 h. Endothelium-dependent NO-mediated
relaxation was tested in these arteries during precontraction
with high potassium (65 mmol/l) in the presence of 10 µmol/l
indometacin. High glucose did not lead to any alterations in
precontraction (active wall tension in response to 65 mmol/l
potassium was 2.8±0.6 N/m). Pre-incubation with 30 or
40 mmol/l glucose reduced acetylcholine-induced vaso-
relaxation (Fig. 1a). The efficacy significantly decreased
(Emax in presence of 5, 30 and 40 mmol/l glucose was 67±2,
56±3 and 50±3% vasorelaxation, respectively; p<0.01), but
the potency of acetylcholine was not altered (pD2 in presence
of 5, 30 and 40 mmol/l glucose 6.6±0.1, 6.7±0.1 and
6.5±0.1, respectively). This effect of glucose was not due to
changes in osmotic values as indicated by normal relaxing
responses to the osmotic control mannitol (Emax 65±3%,
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endothelium-dependent, because no alterations in
endothelium-independent relaxation were provoked with
the NO-donor SNP (Fig. 1b).
To study whether intracellular accumulation of methyl-
glyoxal is involved in high glucose-induced impairment of
acetylcholine-induced vasorelaxation, mesenteric arteries of
rats with transgenic overexpression of the cytosolic GLO-I
enzyme were used. In these transgenic rats we measured a
significant increase (p<0.001) in GLO-I activity in the
mesenteric arteries compared with their wild-type litter-
mates (Fig. 1c). GLO-I overexpression prevented high
glucose-induced impairment of endothelium-dependent
NO-mediated relaxation (Fig. 1d), indicating that methyl-
glyoxal is involved in high glucose-induced impairment of
vasorelaxation. To test whether methylglyoxal is also
involved in hyperglycaemia-induced impairment of vascu-
lar reactivity in vivo, we tested acetylcholine-induced
vasorelaxation in the mesenteric arteries of wild-type and
transgenic GLO-I rats with or without diabetes. Wild-type
diabetic rats had decreased vascular reactivity to acetyl-
choline (and not to SNP; data not shown), which was
improved by GLO-I overexpression (Fig. 1e). The potency
of acetylcholine in the mesenteric arteries was markedly
decreased in wild-type diabetic rats and significantly
improved by GLO-I overexpression in transgenic rats
(Fig. 1f).
Extracellularly added methylglyoxal-derived AGEs do not
lead to impaired vasoreactivity To test a possible extracel-
lular contribution of methylglyoxal-derived AGEs to
vascular reactivity, methylglyoxal-modified albumin was
added to the mesenteric arteries. Minimally and highly
modified methylglyoxal-albumin was prepared by incubat-
ing albumin with 0.5 and 10 mmol/l methylglyoxal
respectively for 2, 4 or 8 days. Concentrations of the AGEs
CML, CEL and MG-H1 in the albumin preparations
incubated for 2 days are shown in Fig. 2a–c. None of these
methylglyoxal-albumin preparations modified contractile
responses or acetylcholine-induced vasorelaxation in rat
mesenteric resistance arteries, demonstrating that vaso-
reactivity is not functionally impaired by extracellular
methylglyoxal-modified albumin adducts (Fig. 2d). Also
albumin modified with methylglyoxal for 4 or 8 days did
not affect reactivity compared with control albumin (data
not shown). In contrast, under the same experimental
conditions, the RAGE ligand S100b significantly (p<0.01)
reduced acetylcholine-induced NO-mediated vasorelaxation
in a dose-dependent manner (Fig. 2e).
Methylglyoxal leads to impaired endothelium-dependent
vasorelaxation To determine the direct effect of methyl-
glyoxal on vasoreactivity, rat mesenteric resistance arteries
were exposed to methylglyoxal. The average isometric
tension generated by the vessels during precontraction with
high potassium (65 mmol/l) was 3.1±0.5 N/m and did not
significantly differ between the various incubations. Preincu-
bationofthe arterieswithmethylglyoxal significantlyreduced
acetylcholine-induced vasorelaxation in the presence of
10 µmol/l indometacin in a concentration-dependent manner
(Fig. 3a), as indicated by a significantly decreased efficacy
(Emax in presence of 0, 0.1, 0.33 and 1.0 mmol/l methyl-
glyoxal 62±3, 57±1, 48±3 and 39±3%, respectively;
p<0.001). In contrast, the potency of acetylcholine was not
altered (pD2 in presence of 0, 0.1, 0.33 and 1.0 mmol/l
methylglyoxal 6.5±0.1, 6.3±0.1, 6.2±0.1 and 6.3±0.2, respec-
tively). Longer incubations with lower amounts of methyl-
glyoxal (10 and 50 µmol/l for 2 h) also impaired NO-mediated
vasorelaxation as indicated by decreased efficacy (Emax in
presence of 0, 10 and 50 µmol/l methylglyoxal 58±2, 55±2
and 46±3%, respectively; p<0.01; Fig. 3b). The impairment
of acetylcholine-induced vasorelaxation by methylglyoxal was
endothelium-dependent, as indicated by normal relaxing
responses of arteries pre-incubated with methylglyoxal to
the endothelium-independent NO donor SNP (Fig. 3c).
Fig. 2 Effect of methylglyoxal-modified albumin and S100b on
acetylcholine-induced NO-mediated endothelium-dependent relaxation
in isolated rat mesenteric arteries. a–c Characteristics of methylglyoxal-
modified albumin (MMA). Control albumin (CA) was exposed to
methylglyoxal (0.5 and 10 mmol/l) for 2 days to prepare minimally
modified methylglyoxal-albumin and highly modified methylglyoxal-
albumin (HMA). The amount of CML (a), CEL (b) and MG-H1 (c)w a s
determined by UPLC-MSMS analysis. d Acetylcholine (ACh)-induced
NO-mediated endothelium-dependent relaxation during incubation with
albumin (black squares), minimally modified methylglyoxal-albumin
(white circles) and highly modified methylglyoxal-albumin (black
circles) did not statistically differ from the control group (white
squares); n=4. e Incubation of mesenteric arteries with 20 (white
circles) or 40 µg/ml (black circles) of the RAGE ligand S100b resulted
in concentration-dependent impairment of acetylcholine-induced
NO-mediatedendothelium-dependentrelaxation.The40µg/mlincubation
resulted in a statistically significant shift of the dose–response curve;
*p<0.05 vs control group, n=4
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accumulation of the major methylglyoxal-derived AGE, MG-
H1, which was predominantly localised in the adventitia and
the endothelium (Fig. 3d–g). To confirm the accumulation of
MG-H1 by methylglyoxal treatment and to further address
the localisation of MG-H1 in endothelial cells, we incubated
endothelial cells with methylglyoxal and showed intracellu-
lar localisation of MG-H1 predominantly in the cytoplasm
and the nucleus of these endothelial cells (Fig. 3i). MG-H1
accumulation of methylglyoxal in mesenteric arteries was
Fig. 3 Effect of methylglyoxal on vascular reactivity and intracellular
MG-H1 formation. a Incubation of isolated mesenteric arteries for 1 h
with 0.1 mmol/l (black squares), 0.33 mmol/l (white circles) and
1.0 mmol/l (black circles) methylglyoxal resulted in impairment of
acetylcholine (ACh)-induced NO-mediated endothelium-dependent relax-
ation compared with the control group (white squares); n=5 for all
conditions. Incubation with 0.33 mmol/l and 1.0 mmol/l methylglyoxal
resulted in a statistically significant shift of the dose–response curve
(*p<0.05 and ***p<0.001 respectively vs control group; n=5). b
Incubation of isolated mesenteric arteries for 2 h with 10 µmol/l (black
squares) and 50 µmol/l (black circles) methylglyoxal resulted in
impairment of acetylcholine-induced NO-mediated endothelium-
dependent relaxation compared with the control group (white squares);
n=4 for all conditions. Incubation with 50 µmol/l methylglyoxal resulted
in a statistically significant shift of the dose–response curve (**p<0.01vs
control group; n=4). c SNP-induced NO-mediated endothelium-
independent vasorelaxation during incubation without (white squares) or
with 1.0 mmol/l methylglyoxal (black circles) for 1 h did not differ (n=4).
d–i Localisation of MG-H1 in adventitia and endothelial cells of
mesenteric arteries not incubated (d)o ri n c u b a t e dw i t h0 . 1m m o l / l( e),
0.33 mmol/l (f)o r1 . 0m m o l / l( g) methylglyoxal for 1 h. Intracellular
localisation of MG-H1 was also determined by confocal laser scanning
microscopy in cultured endothelial cells (ECRF24) incubated without (h)
or with 1.0 mmol/l methylglyoxal (i)f o r1h .j Quantification of MG-
H1 staining in arteries exposed to methylglyoxal (n=4). k
Concentration-dependent increase of MG-H1 levels in protein
lysates of mesenteric arteries not incubated (Control) or incubated
with 0.1, 0.33 or 1.0 mmol/l methylglyoxal (MGO) for 1 h as
determined by UPLC-MSMS (n=3). j, k **p<0.01 and ***p<0.001
vs control group. AU, arbitrary units
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immunostaining of MG-H1 (Fig. 3j) and by UPLC-MSMS
(Fig. 3k). These experiments demonstrated that extracellu-
larly added methylglyoxal results in intracellular accumula-
tion of MG-H1.
Intracellular effects of methylglyoxal contribute to
methylglyoxal-induced impairment of endothelium-
dependent vasorelaxation To study whether the intracellular
accumulation of methylglyoxal and/or MG-H1 is involved in
methylglyoxal-induced impairment of acetylcholine-induced
vasorelaxation, arteries of GLO-I transgenic rats were
incubated with 1.0 mmol/l methylglyoxal. These arteries
did not show elevated MG-H1 levels, while methylglyoxal-
incubated arteries of wild-type rats did (Fig. 4a–d). Further-
more, the impaired vasoreactivity of methylglyoxal-incubated
mesenteric arteries of rats was normalised by GLO-I over-
expression (Fig. 4e), indicating that extracellularly added
methylglyoxal leads to intracellular processes that con-
tribute to methylglyoxal-impaired endothelium-dependent
vasorelaxation.
Methylglyoxal incubation leads to increased peroxynitrite
via formation of reactive oxygen species To investigate a
possible role of ROS in the impairment of acetylcholine-
induced vasorelaxation by methylglyoxal, we stained rat
mesenteric arteries for nitrotyrosine after exposure to the
endothelial nitric oxide synthase (eNOS) stimulus acetyl-
choline (Fig. 5a–d). Nitrosylation of tyrosine residues is a
well-known marker for peroxynitrite formation, an oxidant
product of NO. In parallel to MG-H1 accumulation, we
observed that methylglyoxal resulted in an increase in
nitrotyrosine staining in the same dose-dependent manner
(Fig. 5e). This staining was not limited to specific regions
of the vessel wall. Methylglyoxal-induced peroxynitrite
formation was inhibited by treatment of the arteries with the
NOS blocker L-NAME (data not shown).
To confirm that methylglyoxal contributes to ROS produc-
tion in the endothelium, we used a fluorescent probe in
endothelial cells to monitor ROS production. In CM-
H2DCFDA-loaded endothelial cells, methylglyoxal treatment
resulted in a concentration-dependent increase in oxidative
stress formation (Fig. 5f). Direct incubation of the DCF
probe with methylglyoxal did not lead to any increase in
fluorescent signal, thereby excluding a non-specific methyl-
glyoxal effect (data not shown). To exclude possible
cytotoxic effects of methylglyoxal on the endothelial cells,
we performed a cell viability assay. The MTT assay showed
no significant levels of cytotoxicity after 1 h treatment with
0.1, 0.33 and 1.0 mmol/l methylglyoxal (100±4%, 98±3%
and 97±5% viability compared with control cells, respec-
tively). In addition, eNOS staining of the mesenteric arteries
also showed that the endothelial cell layer remained intact
after exposure to 1.0 mmol/l methylglyoxal. There were no
signs of apoptosis as indicated by absence in the staining of
the apoptotic marker cleaved caspase-3 (data not shown).
We also investigated whether free methylglyoxal or
methylglyoxal-derived AGEs have a direct effect on NO.
Free methylglyoxal, but not highly modified methylglyoxal-
albumin, did lead to increased breakdown of NO (Fig. 5g).
Under the conditions used, the reaction between methyl-
glyoxal and NO could be fitted according to a (pseudo) first-
order reaction (log k = 1.05 ± 0.13 mol l
−1 s
−1). The results
show that methylglyoxal reduced the half-life of NO in
buffer from 4.3±0.1 min to approximately 0.8±0.2 min. In
comparison, under the same experimental conditions, the rate
Fig. 4 Effect of GLO-I overexpression on methylglyoxal (MGO)-
induced formation of the major methylglyoxal-adduct MG-H1 and on
vascular reactivity. a–d Compared with MG-H1 staining in mesenteric
arteries of wild-type rats incubated without (a) and with 1.0 mmol/l
methylglyoxal (b), incubation for 1 h with 1.0 mmol/l methylglyoxal
did not lead to intracellular MG-H1 formation in GLO-I transgenic rats
incubated without (c) and with 1.0 mmol/l methylglyoxal (d). e In
mesenteric arteries of GLO-I transgenic rats, acetylcholine (ACh)-
induced NO-mediated endothelium-dependent relaxation was not
impaired during incubation with 1.0 mmol/l methylglyoxal (black
circles) for 1 h compared with control incubation (white squares) (n=4)
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haemoglobin was 1.0 ×10
4 mol l
−1 s
−1 [32].
Antioxidant treatment prevents impaired vasorelaxation by
methylglyoxal The results so far suggest a reduction of NO
bioavailability by methylglyoxal via induction of ROS
formation. In line with this, pre-incubation of the mesenteric
arteries with the antioxidants EUK-134, Mn(III)TMP and
NAC prevented methylglyoxal impairment of acetylcholine-
induced vasorelaxation (Fig. 6a). In addition, preincubation
with the NAD(P)H oxidase inhibitor apocynin prevented
decreased vascular relaxation (ESM Fig. 1).Vessels incubated
with antioxidants showed less nitrotyrosine staining upon
incubation with 1.0 mmol/l methylglyoxal (Fig. 6b–f, g), but
MG-H1 levels were not altered (Fig. 6h). In accordance, in
cultured endothelial cells, the antioxidants also led to
reduction of methylglyoxal-induced oxidative stress as
measured with the CM-H2DCFDA probe (Fig. 6i).
Discussion
In this study we have shown that hyperglycaemia-induced
impairment of endothelium-dependent NO-mediated vaso-
relaxation of mesenteric arteries is mediated by the major
AGE precursor methylglyoxal. The effect of methylglyoxal
occurs intracellularly and is most likely to be caused by
decreased bioavailability of NO due to a methylglyoxal-
induced increase of oxidative stress. These data provide a
mechanisticlinkbetweenhyperglycaemia,theformationofthe
AGE precursor methylglyoxal and vascular complications.
Endothelial dysfunction is characterised by impaired
vascular response to endothelium-derived NO and is
associated with the development of micro- and macro-
vascular complications in diabetes [33]. To gain insight into
the mechanism by which hyperglycaemia alters endothelial
function, we used acetylcholine, which stimulates the
release of NO from endothelial cells, leading to relaxation
of the underlying smooth muscle cells. Experiments were
performed in the presence of indometacin and elevated K
+
concentration to rule out involvement of endothelium-
derived prostaglandins and hyperpolarising factors, and
thus to focus on NO-mediated relaxation. Treatment of
arteries with high concentrations of glucose significantly
decreased acetylcholine-induced NO-mediated vasorelaxa-
tion (Fig. 1), which is in agreement with a previous study
performed in mesenteric arteries [34]. We also found that
the effect of high glucose was prevented in arteries with
GLO-I overexpression and that the impaired relaxation in
diabetic rats was improved by GLO-I overexpression. In
addition, incubation with exogenous methylglyoxal resulted
in dose-dependent impairment of acetylcholine-induced
vasorelaxation (Fig. 3). These data from ex vivo and in
vivo experiments provide strong evidence that the impair-
Fig. 5 Methylglyoxal (MGO)-induced oxidative stress formation in
isolated mesenteric arteries and cultured endothelial cells, and direct
quenching of NO. a–d Representive staining of nitrotyrosine (NT) in
mesenteric resistance arteries not incubated (a) or incubated for 1 h
with 0.1 mmol/l (b), 0.33 mmol/l (c) or 1.0 mmol/l (d) methylglyoxal.
e Quantification of NT staining in methylglyoxal-incubated arteries
(n=4). f Oxidative stress formation in endothelial cells as measured
with a CM-H2DCFDA probe during treatment for 1 h with
methylglyoxal as shown; n=3. g Direct effect of methylglyoxal
(MGO) and methylglyoxal-modified human albumin (HSA-MGO) on
NO as measured with an Iso-NO meter in deoxygenated buffer.
*p<0.05 and ***p<0.001 vs control group. AU, arbitrary units
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tion in diabetes is mediated by the major AGE precursor
methylglyoxal.
Since the arterial contractile responses to K
+ and relaxing
responses to the NO-donor SNP were not modified by
methylglyoxal, our data indicate that short exposure to
methylglyoxal leads to an endothelium-dependent effect on
vasorelaxation without a direct effect of methylglyoxal on
arterial smooth muscle function. In accordance, Mukohda et
al. showed that methylglyoxal had no effects on K
+-induced
contraction [35]. Although not tested in our study, chronic
exposure to exogenous methylglyoxal may also lead to
impaired endothelium-independent vasorelaxation [36].
We did not find any effects of extracellularly added
methylglyoxal-modified albumin on vascular reactivity
(Fig. 2). In accordance with this result, we had previously
demonstrated that there is also no binding and biological
effect of methylglyoxal-modified albumin on endothelial
cells [37]. In contrast, Xu et al. [11] showed that other
extracellularly formed AGEs can impair endothelium-
dependent vasorelaxation, but these data were obtained
with AGE-albumin, which was prepared with a degree of
modification that is much higher than that ever seen in
diabetes. A recent paper by Gao et al. [38] described the
importance of S100b-induced RAGE activation in endo-
thelial dysfunction and impaired vasoreactivity. We con-
Fig. 6 Effect of antioxidants on the effect of methylglyoxal on
vascular reactivity and oxidative stress formation. a Acetylcholine
(ACh)-induced NO-mediated endothelium-dependent relaxation
during incubation without (white squares) or with 1.0 mmol/l methyl-
glyoxal (black circles) for 1 h with or without pre-incubation for
20 min with the antioxidants NAC (1.0 mmol/l) (white diamonds),
EUK-134 (1 µmol/l) (black squares) or Mn(III)TMP (1 µmol/l) (white
circles). Treatment of mesenteric arteries with 1.0 mmol/l methyl-
glyoxal in the absence of antioxidant resulted in a significant shift
in the dose–response curve compared with the control group
(***p<0.001). All antioxidant pretreatments prevented methylglyoxal-
induced impairment of reactivity (n=5). b–f Nitrotyrosine staining of
arteries incubated without (b), or with 1.0 mmol/l methylglyoxal (c)a n d
after pre-incubation with 1.0 mmol/l NAC (d), 1 µmol/l EUK-134 (e)o r
1 µmol/l Mn(III)TMP (f). g Quantification of NT staining in mesenteric
arteries after treatment with 1.0 mmol/l methylglyoxal (MGO) without or
with pre-incubation NAC, EUK-134 or Mn(III)TMP (n=4).h Quantifica-
tion of MG-H1 staining in mesenteric arteries after treatment with
1.0 mmol/l methylglyoxal without or with pre-incubation at the same
concentrations of NAC, EUK-134 or Mn(III)TMP. i Oxidative stress
formation measured with a CM-H2DCFDA probe in ECRF24 cells after
treatment with 1.0 mmol/l methylglyoxal without or withpre-incubationat
100 µmol/l NAC, 10 nmol/l EUK-134 and 10 nmol/l Mn(III)TMP (n=3).
g–i ***p<0.001 vs control group; †p<0.001 vs methylglyoxal group.
AU, arbitrary units
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acetylcholine-induced NO-mediated vasorelaxation
(Fig. 2e). Combined, these data provide strong evidence
that extracellular methylglyoxal-derived AGEs are not
involved in diabetic arterial dysfunction and that other
ligands for RAGE, such as CML and S100b, impair
endothelium-dependent vasorelaxation.
Another important finding of our study is that the effect
of hyperglycaemia and methylglyoxal on NO-mediated
vasorelaxation in rat mesenteric arteries is completely
abolished in rat mesenteric arteries with overexpression of
GLO-I, indicating that the effect of hyperglycaemia and
exogenous methylglyoxal is due to intracellular effects of
methylglyoxal in endothelial cells. We recently found that
endothelial cells incubated with high glucose concentra-
tions display an increase in methylglyoxal [18] and we have
now demonstrated that methylglyoxal leads to intracellular
accumulation of the major methylglyoxal-induced AGE,
MG-H1. This is in agreement with a study showing that
methylglyoxal, given intraperitoneally to rats for 7 weeks,
induces an increase in vascular AGE content [36]. In our
study, MG-H1 appeared to be localised in the cytoplasm
and in the nucleus of endothelial cells. The latter is in
accordance with data of two recent papers about methyl-
glyoxal modification of nuclear proteins [39, 40]. Further-
more, Schlotterer et al. [41] recently reported that
hyperglycaemia leads to methylglyoxal-modified mitochon-
drial proteins and reduced lifespan in C. elegans. This
oxidative stress-dependent process was inhibited by GLO-I
overexpression, thereby linking methylglyoxal to the
formation of ROS.
Chronic hyperglycaemia is associated with increased
intracellular levels of methylglyoxal [18, 42], oxidative
stress [43, 44] and an impairment of NO synthesis
pathways [45]. Our results link these studies by showing
an oxidative stress-dependent effect of methylglyoxal on
NO bioavailability. This impairment was prevented by
superoxide dismutase mimetics and by the antioxidant
NAC (Fig. 6). Moreover, the impaired relaxation could
also be prevented by apocynin, but because of the lack of
specificity of this NAD(P)H inhibitor [46], the exact
mechanism by which methylglyoxal induces the formation
of ROS is not completely clear. Although not addressed in
this study, methylglyoxal modifications of mitochondrial
membrane proteins [27], antioxidant enzymes [47] and
GAPDH [48] may increase oxidative stress and, as a
consequence,impairendothelium-dependentvasorelaxation.
Because AGEs are known to inactivate NO by a direct
chemical reaction, the impaired endothelium-dependent
vasodilatation in diabete sm a yb em e d i a t e db yN O
quenching and NO depletion by methylglyoxal-derived
AGE accumulation [49]. Indeed, we observed quenching of
NO by methylglyoxal, but not by methylglyoxal-derived
AGEs. Methylglyoxal reduced the half-life of NO in buffer
from 4 to approximately 1 min. However, in vivo the very
fast reaction of NO with numerous bio-molecules, such as
haemoglobin, is one of the reasons why the half-life of NO
in biological systems is very short, i.e. less than 1 s [50],
and not susceptible to being shortened by methylglyoxal.
Therefore, the physiological relevance of quenching of NO
by methylglyoxal, for example in methylglyoxal-induced
impairment of endothelium-dependent vasodilatation, is
very limited. Methylglyoxal and methylglyoxal-derived
AGEs may also decrease NO availability by decreasing
NO synthase activity, but in our previous study we already
ruled out the possibility that free methylglyoxal and the
methylglyoxal-derived AGEs argpyrimidine and MG-H1,
which have some structural homology with the NOS
inhibitor asymmetric dimethylarginine, directly inhibit
eNOS activity [51]. Together, these findings indicate that
the effects of methylglyoxal on vasoreactivity are thus
caused by methylglyoxal-induced oxidative stress and the
quenching of NO by oxidative stress, rather than direct
interaction of methylglyoxal-adducts with NO or eNOS
activity. The question of whether methylglyoxal or
methylglyoxal-induced AGEs are involved in impaired
eNOS activation by oxidative-stress-related interference
with eNOS phosphorylation needs to be further investigated.
For the ex vivo and in vitro experiments, we used
methylglyoxal in a range of 10 to 1,000 µmol/l, a range that
caused effects in a concentration-dependent manner. The in
vivo concentration of methylglyoxal is under debate;
plasma methylglyoxal levels are estimated to be about
0.5 µmol/l in healthy individuals and can increase twofold
in diabetes [52], while others have demonstrated that
plasma methylglyoxal concentration in poorly controlled
human diabetic patients is about 400 µmol/l [53]. Never-
theless, cells produce large amounts of methylglyoxal [54]
and therefore intracellular levels are probably much higher
than plasma levels [55]. Although the maximum concen-
tration of methylglyoxal used in the present study appears
to be higher than levels observed in vivo, this concentration
was also used to increase intracellular concentrations and to
mimic life time exposure to elevated levels of methyl-
glyoxal such as in diabetes and in hypertension. Under our
experimental conditions, exposure to elevated methyl-
glyoxal levels did not lead to cytotoxic effects.
What are the clinical implications of these observations?
Because higher plasma levels of methylglyoxal have been
demonstrated under postprandial conditions [36]a n di n
plasma of diabetic patients [17], as well as in endothelial
cells incubated with high glucose concentrations [18, 43], we
propose here that methylglyoxal plays a crucial role in
impaired endothelium-dependent vasorelaxation under post-
prandial conditions and in chronic hyperglycaemia, and in
the long term in development of vascular complications.
998 Diabetologia (2010) 53:989–1000In summary, we found that hyperglycaemia-induced impair-
ment of endothelium-dependent NO-mediated vasorelaxation
is prevented by GLO-I overexpression and that methylglyoxal
decreased NO-mediated vasorelaxation due to an increase in
oxidative stress. We conclude that hyperglycaemia-induced
impairment of endothelium-dependent vasorelaxation is
mediated by intracellular methylglyoxal levels in an oxidative
stress-dependent pathway. These data provide a new mecha-
nistic link between hyperglycaemia, the formation of
methylglyoxal-derived AGEs and vascular complications.
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